Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Glioma

Not applicable

Cell-based and mouse studies suggest a chimeric vesicular stomatitis virus (VSV)-based oncolytic virus could help treat glioma. The VSV glycoprotein in wild-type VSV was replaced with a variant glycoprotein from lymphocytic choriomeningitis virus to create rVSV(GP). In multiple tumor cell lines, rVSV(GP) had cytotoxic potency comparable to that of wild-type VSV. In mice, rVSV(GP) did not elicit neurotoxicity associated with wild-type VSV. In a mouse model of human glioma, rVSV(GP) increased survival compared with wild-type VSV. Next steps could include IND-enabling safety studies.

SciBX 7(24); doi:10.1038/scibx.2014.703
Published online June 19, 2014

Patent and licensing status unavailable

Muik, A. et al. Cancer Res.;
published online May 8, 2014;
doi:10.1158/0008-5472.CAN-13-3306
Contact: Dorothee von Laer, Medical University Innsbruck, Innsbruck, Austria
e-mail:
dorothee.von-laer@i-med.ac.at